VIR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VIR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Vir Biotechnology's gross profit for the three months ended in Dec. 2023 was $8.80 Mil. Vir Biotechnology's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $36.73 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Vir Biotechnology's gross profit for the three months ended in Dec. 2023 was $8.80 Mil. Vir Biotechnology's Revenue for the three months ended in Dec. 2023 was $9.60 Mil. Therefore, Vir Biotechnology's Gross Margin % for the quarter that ended in Dec. 2023 was 91.69%.
Vir Biotechnology had a gross margin of 91.69% for the quarter that ended in Dec. 2023 => Durable competitive advantage
During the past 7 years, the highest Gross Margin % of Vir Biotechnology was 93.94%. The lowest was 90.74%. And the median was 93.00%.
The historical data trend for Vir Biotechnology's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vir Biotechnology Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Gross Profit | Get a 7-Day Free Trial | 0.71 | 67.25 | 1,021.20 | 1,434.15 | 36.73 |
Vir Biotechnology Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Gross Profit | Get a 7-Day Free Trial | 15.79 | 44.81 | -12.74 | -4.14 | 8.80 |
For the Biotechnology subindustry, Vir Biotechnology's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's Gross Profit distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Vir Biotechnology's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit (A: Dec. 2023 ) | = | Revenue | - | Cost of Goods Sold |
= | 39.494 | - | 2.765 | |
= | 36.73 |
Vir Biotechnology's Gross Profit for the quarter that ended in Dec. 2023 is calculated as
Gross Profit (Q: Dec. 2023 ) | = | Revenue | - | Cost of Goods Sold |
= | 9.602 | - | 0.798 | |
= | 8.80 |
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $36.73 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Vir Biotechnology's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as
Gross Margin % (Q: Dec. 2023 ) | = | Gross Profit (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 8.80 | / | 9.602 | |
= | 91.69 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Vir Biotechnology (NAS:VIR) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Vir Biotechnology had a gross margin of 91.69% for the quarter that ended in Dec. 2023 => Durable competitive advantage
Thank you for viewing the detailed overview of Vir Biotechnology's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Svf Endurance (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED, 27 HOSPITAL ROAD, GEORGE TOWN E9 KY1-9008 |
Vicki L Sato | director | 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451 |
Phillip Pang | officer: Chief Medical Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Steven J. Rice | officer: Chief Administrative Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Saira Ramasastry | director | 501 CANAL BLVD., RICHMOND CA 94804 |
Backer Marianne De | officer: Chief Executive Officer | 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105 |
Ann M. Hanly | officer: Chief Technology Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Sung Lee | officer: Chief Financial Officer | 7000 MARINA BLVD, BRISBANE CA 94005 |
Johanna Friedl-naderer | officer: Chief Business Officer, Global | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
George A Scangos | director, officer: President and CEO | C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083 |
Howard Horn | officer: CFO | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Charles Elliott Sigal | director | 32 BREARLY ROAD, PRINCETON NJ 08540 |
Herbert Virgin | officer: EVP, Research & CSO | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Janet Napolitano | director | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Robert J More | director | 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001 |
From GuruFocus
By Marketwired • 10-03-2023
By Business Wire • 12-06-2023
By sperokesalga sperokesalga • 05-02-2023
By sperokesalga sperokesalga • 05-17-2023
By Marketwired • 10-05-2023
By sperokesalga sperokesalga • 06-07-2023
By sperokesalga sperokesalga • 06-05-2023
By Marketwired • 07-26-2023
By Marketwired • 08-29-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.